stockrow
Friday 6 November 2026
Export ENOV’s income statement to Excel — free account
Enovis Corporation
ENOV Healthcare Medical Devices
Enovis Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 6.66% from fiscal 2024.
- Revenue
- +1.79%
- EPS
- +100.6%
- Free cash flow
- +20.3%
- Total debt
- −7.45%
Quarter to September 2026, against a year earlier
27.07
1.55
−5.42%
Follow ENOV
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.46 | 0.52 | 0.57 | 0.68 | |
P/FCF ratio |
15.36 | 18.73 | 36.30 | 76.33 | |
P/Operating CF |
14.95 | 15.89 | 54.44 | 17.17 | |
P/B ratio |
0.71 | 0.81 | 0.88 | 1.02 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.00 | 1.07 | 1.14 | 1.24 | |
EV/EBITDA |
7.49 | 7.98 | 9.44 | 12.65 | |
EV/Operating CF |
8.93 | 9.12 | 10.69 | 12.80 | |
EV/FCF |
33.26 | 38.71 | 72.29 | 139.62 | |
Quick Ratio |
0.76 | 0.74 | 0.78 | 0.80 | |
Current Ratio |
2.15 | 1.98 | 2.04 | 2.02 | |
Net Debt/EBITDA |
0.00 | 14.38 | 16.18 | 16.55 | |
Debt/Assets |
33.68% | 34.11% | 34.60% | 33.82% | |
Debt/Equity |
0.84 | 0.87 | 0.90 | 0.87 | |
Asset Turnover |
0.56 | 0.52 | 0.52 | 0.53 | |
Operating CF/Net income |
22.78 | (63.05) | (2.73) | (0.17) | |
Capex/Depreciation |
0.00 | (0.62) | (0.72) | (0.10) | |
Interest Coverage |
0.44 | 2.17 | 0.71 | (66.84) | |
Research and Development Expense of Revenue |
5.60% | 5.44% | 5.35% | 5.45% | |
Selling, General and Administrative Expense of Revenue |
46.42% | 45.25% | 48.00% | 46.97% | |
Intangible Assets out of Total Assets |
0.48 | 0.49 | 0.50 | 0.51 | |
Share Based Compensation of Revenue |
1.39% | 1.54% | 1.49% | 1.41% | |
Graham Net Nets |
(0.93) | (0.90) | (0.85) | (0.75) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(50.41%) | (93.04%) | (87.38%) | (77.74%) | |
Free Cash Flow Yield |
6.51% | 5.34% | 2.76% | 1.31% | |
Revenue per Share |
9.55 | 10.12 | 10.28 | 10.09 | |
Operating CF per Share |
1.22 | 1.30 | 0.42 | 1.55 | |
Capex per Share |
(0.62) | (0.76) | (0.92) | (0.99) | |
Free Cash Flow per Share |
0.60 | 0.54 | (0.50) | 0.57 | |
Cash per Share |
0.22 | 0.22 | 0.58 | 0.64 | |
Shareholders Equity per Share |
25.57 | 25.68 | 25.81 | 26.14 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
25.57 | 25.68 | 25.81 | 26.14 | |
Free Cash Flow |
34.99 | 31.14 | (28.85) | 32.29 | |
Working Capital |
667.74 | 602.64 | 631.02 | 608.59 | |
Capital Expenditures |
(36.50) | (43.89) | (52.80) | (56.25) | |
Net Current Asset Value |
(992.38) | (1,072.27) | (1,113.08) | (1,135.78) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.07 | 0.08 | 0.09 | 0.10 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
430.03 | 447.77 | 439.91 | 424.91 | |
Average Payables |
199.61 | 203.24 | 200.89 | 183.31 | |
Average Inventory |
616.95 | 614.94 | 594.23 | 565.75 | |
Average Assets |
4,084.46 | 4,393.76 | 4,353.65 | 4,276.76 | |
Average Common Equity |
1,759.63 | 2,030.06 | 2,049.86 | 2,028.12 |
Columns are period end dates · fundamentals updated 5 Nov 2026